1. Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 2016;106:1634-1647. PMID:
27678032.
2. D'Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 2002;17:2787-2794. PMID:
12407029.
3. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901-907. PMID:
10785214.
4. Farquhar C, Marjoribanks J, Brown J, Fauser BC, Lethaby A, Mourad S, et al. Management of ovarian stimulation for IVF: narrative review of evidence provided for World Health Organization guidance. Reprod Biomed Online 2017;35:3-16. PMID:
28501428.
5. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Hum Reprod 1992;7:320-327. PMID:
1587936.
6. Endo T, Honnma H, Hayashi T, Chida M, Yamazaki K, Kitajima Y, et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod 2002;17:2548-2551. PMID:
12351526.
7. Wang YQ, Yu N, Xu WM, Xie QZ, Yan WJ, Wu GX, et al. Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: a controlled clinical study. Exp Ther Med 2014;8:1855-1860. PMID:
25371744.
8. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online 2007;15:408-412. PMID:
17908403.
9. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Iliadis GS, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online 2009;18:15-20.
10. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Alexopoulou E, et al. Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase. Reprod Biomed Online 2009;19:789-795. PMID:
20031018.
11. Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Tarlatzi TB, et al. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrinol 2012;10:69PMID:
22938051.
12. Hosseini MA, Mahdavi A, Aleyasin A, Safdarian L, Bahmaee F. Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study. Gynecol Endocrinol 2012;28:853-855. PMID:
22697477.
13. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003;9:77-96. PMID:
12638783.
14. Schenker JG. Prevention and treatment of ovarian hyperstimulation. Hum Reprod 1993;8:653-659. PMID:
8314955.
15. Levin I, Almog B, Avni A, Baram A, Lessing JB, Gamzu R. Effect of paracentesis of ascitic fluids on urinary output and blood indices in patients with severe ovarian hyperstimulation syndrome. Fertil Steril 2002;77:986-988. PMID:
12009355.
16. Lan KC, Huang FJ, Lin YC, Kung FT, Lan TH, Chang SY. Significantly superior response in the right ovary compared with the left ovary after stimulation with follicle-stimulating hormone in a pituitary down-regulation regimen. Fertil Steril 2010;93:2269-2273. PMID:
19200958.
17. Choe SA, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM, et al. Symmetry in number of retrieved oocytes between two ovaries: a possible predictor of in vitro fertilization outcome. Gynecol Endocrinol 2011;27:997-1000. PMID:
21627556.
18. Fukuda M, Fukuda K, Andersen CY, Byskov AG. Characteristics of human ovulation in natural cycles correlated with age and achievement of pregnancy. Hum Reprod 2001;16:2501-2507. PMID:
11726566.
19. Potashnik G, Insler V, Meizner I, Sternberg M. Frequency, sequence, and side of ovulation in women menstruating normally. Br Med J (Clin Res Ed) 1987;294:219.
20. Dominguez R, Cruz ME, Chavez R. Differences in the ovulatory ability between the right and left ovary are related to ovarian innervation. In: Hirshfield AN, editors. Growth factors and the ovary. Boston (MA): Springer; 1989. p. 321-325.
21. Latouche J, Crumeyrolle-Arias M, Jordan D, Kopp N, Augendre-Ferrante B, Cedard L, et al. GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 1989;125:1739-1741. PMID:
2547594.
22. Minaretzis D, Jakubowski M, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 1995;80:430-434. PMID:
7852501.
23. Asimakopoulos B, Nikolettos N, Nehls B, Diedrich K, Al-Hasani S, Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril 2006;86:636-641. PMID:
16904114.
24. Taylor PD, Hillier SG, Fraser HM. Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. J Endocrinol 2004;183:1-17. PMID:
15525569.
25. Fridén BE, Nilsson L. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization. Acta Obstet Gynecol Scand 2005;84:812-816. PMID:
16026411.
26. Del Canto F, Sierralta W, Kohen P, Muñoz A, Strauss JF 3rd, Devoto L. Features of natural and gonadotropin-releasing hormone antagonist-induced corpus luteum regression and effects of in vivo human chorionic gonadotropin. J Clin Endocrinol Metab 2007;92:4436-4443. PMID:
17698899.